Alembic Starts Construction of
new R&D center
(Date: 2'nd June'03)
The civil work of the new R&D Centre at Vadodara,
Gujarat has commenced on the 2nd of june 2003.
The new Research Centre would offer
state-of-the-art research infrastructure having
a carpet area of 80,000 square feet.
The facility would consist of Chemistry,
Analytical and Biological Laboratories. An
Animal House facility for the pharmacological
and toxicological studies in rodents is also
being created.
The R&D Center would house an Information center
subscribing to latest books, international and
national journals with in-house access to Sci-finder
and STN.
ALEMBIC BETS BIG ON CONTRACT RESEARCH
Source: Economic Times (Date:30'th April' 03)
Alembic, a Baroda-based pharma
company, has scripted a major thrust on
contract research as part of its
strategy to increase its presence in the
segment.
Alembic has entered a contract research
agreement with Chiron Corporation, a
research-based pharmaceuticals company
headquartered at Emeryville, California.
The agreement, which has been signed
between these two companies, will seek
to use the expertise offered by Alembic
in the field of heterocyclic chemistry.
Based on Alembic's research, Chiron will
develop new drugs for different
therapeutic segments.
"Besides Chiron Corporation, we are also
talking to a couple of foreign companies
for contract research," HT Patel, senior
VP, Alembic, told ET. The company seeks
to boost its revenues by focusing on
contract research and by utilising its
R&D base, Mr Patel said.
It may be pointed out that like
multinational IT companies, many foreign
companies have started using the R&D
base of Indian pharmaceutical companies
to develop new drugs. As foreign
companies have started outsourcing
molecules from Indian companies, the
market size of contract research is
growing at a rate of 100%, a pharma
analyst said. At present, market size of
contract research in the country is
around Rs 100 crore and as many 18
companies are engaged in contract
research.
Alembic, which has core concentration on
bulk drugs and formation for human
health and veterinary segments, is also
restructuring its business to focus on
three strategic areas - nutraceuticals,
antidiabetics and antibiotics - which
will be the key drivers for growth in
the coming years. The company has
recently set up a new division for
cardiovascular and diabetic drugs as
well.
The company is planning to launch its
new drugs in these segments and is
targeting the highly regulative markets
like US and Europe for its new drugs.
Alembic enters into contract research agreement with Chiron Corp - California
Source: Economic Times (Date: 5'th Nov' 02)
Alembic Ltd has informed BSE that the company
has entered into contract research agreement
with Chiron Corporation, a Research based
pharmaceutical company headquartered in
Emeryville, California.
Chiron applies its
advanced understanding of the biology of cancer
and infectious disease to develop products from
its flatforms in proteins, small molecules and
vaccines. The multi year agreement will seek to
utilize the expertise offered by company in the
field of Heterocyclic chemistry.
Alembic and Chiron enter into a research pact
Source: EconomicTimes (Date: 4'th Nov'02)
Mumbai : Alembic has tied up with
Chiron Corporation of the US for
contract research. The multi-year deal
seek to use expertise offered by the US
firm in the field of heterocyclic
chemistry. Chiron Corporation, applies
its advanced understanding of the
biology of cancer and other infectious
diseases to develop products from its
flatforms in proteins, small molecules
and vaccines.
Alembic`s research and development team
mainly targets on microbial research,
reverse engineering, process
improvement, new chemical entities and
development of new formulations. The
company has been spending around 2-3 per
cent of its turnover on research and
development efforts. Alembic spent
around Rs 14.41 crore, or 2.31 per cent
of its turnover, on R&D.
The company develops non-infringing
patentable routes of manufacturing
drugs, whose existing patents are set to
expire in the near future. Alembic also
plans to do substantial research work in
the area of new chemical entities to
find potent macrolides. Similar project
has already been initiated in
association with the National Chemicals
Laboratory
